KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Rad Laboratories (BIO) Change in Receivables (2016 - 2026)

Bio-Rad Laboratories has reported Change in Receivables over the past 18 years, most recently at $614.1 million for Q1 2026.

  • Quarterly Change in Receivables fell 4.05% to $614.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.6 billion through Mar 2026, up 2.96% year-over-year, with the annual reading at $2.7 billion for FY2025, 4.05% up from the prior year.
  • Change in Receivables was $614.1 million for Q1 2026 at Bio-Rad Laboratories, down from $697.7 million in the prior quarter.
  • Over five years, Change in Receivables peaked at $717.4 million in Q4 2022 and troughed at $614.1 million in Q1 2026.
  • The 5-year median for Change in Receivables is $655.5 million (2024), against an average of $659.2 million.
  • Year-over-year, Change in Receivables dropped 10.72% in 2022 and then grew 10.38% in 2025.
  • A 5-year view of Change in Receivables shows it stood at $717.4 million in 2022, then decreased by 5.68% to $676.7 million in 2023, then dropped by 6.59% to $632.1 million in 2024, then increased by 10.38% to $697.7 million in 2025, then fell by 11.98% to $614.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Change in Receivables are $614.1 million (Q1 2026), $697.7 million (Q4 2025), and $653.8 million (Q3 2025).